CN113056465B - 经四氢吡喃(thp)取代的双环嘧啶二酮化合物 - Google Patents

经四氢吡喃(thp)取代的双环嘧啶二酮化合物 Download PDF

Info

Publication number
CN113056465B
CN113056465B CN201980071171.4A CN201980071171A CN113056465B CN 113056465 B CN113056465 B CN 113056465B CN 201980071171 A CN201980071171 A CN 201980071171A CN 113056465 B CN113056465 B CN 113056465B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
fluoro
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980071171.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113056465A (zh
Inventor
M·格里洛
B·凯恩
J·奥斯洛布
钟民
F·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Priority to CN202510034967.XA priority Critical patent/CN119977962A/zh
Priority to CN202510034970.1A priority patent/CN119977963A/zh
Publication of CN113056465A publication Critical patent/CN113056465A/zh
Application granted granted Critical
Publication of CN113056465B publication Critical patent/CN113056465B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hospice & Palliative Care (AREA)
CN201980071171.4A 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物 Active CN113056465B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510034967.XA CN119977962A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物
CN202510034970.1A CN119977963A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752278P 2018-10-29 2018-10-29
US62/752278 2018-10-29
PCT/US2019/058297 WO2020092208A1 (en) 2018-10-29 2019-10-28 Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510034970.1A Division CN119977963A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物
CN202510034967.XA Division CN119977962A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物

Publications (2)

Publication Number Publication Date
CN113056465A CN113056465A (zh) 2021-06-29
CN113056465B true CN113056465B (zh) 2025-01-28

Family

ID=68841171

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980071171.4A Active CN113056465B (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物
CN202510034970.1A Pending CN119977963A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物
CN202510034967.XA Pending CN119977962A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510034970.1A Pending CN119977963A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物
CN202510034967.XA Pending CN119977962A (zh) 2018-10-29 2019-10-28 经四氢吡喃(thp)取代的双环嘧啶二酮化合物

Country Status (29)

Country Link
US (5) US11034693B2 (https=)
EP (3) EP4736855A2 (https=)
JP (3) JP7447110B2 (https=)
KR (2) KR102797129B1 (https=)
CN (3) CN113056465B (https=)
AR (1) AR116880A1 (https=)
AU (2) AU2019373206B2 (https=)
BR (1) BR112021008077A2 (https=)
CA (1) CA3118293A1 (https=)
CL (1) CL2021001083A1 (https=)
CO (1) CO2021005540A2 (https=)
DK (2) DK3873904T3 (https=)
EA (1) EA202191152A1 (https=)
ES (1) ES2986923T3 (https=)
FI (2) FI3873904T3 (https=)
HR (2) HRP20241065T1 (https=)
HU (1) HUE068265T2 (https=)
IL (2) IL325304A (https=)
LT (2) LT3873904T (https=)
MX (2) MX2021004955A (https=)
PE (1) PE20211780A1 (https=)
PL (1) PL3873904T3 (https=)
PT (1) PT3873904T (https=)
RS (1) RS65963B1 (https=)
SG (1) SG11202104218SA (https=)
SI (2) SI3873904T1 (https=)
SM (1) SMT202400358T1 (https=)
TW (3) TW202521537A (https=)
WO (1) WO2020092208A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088347A1 (en) 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiii.beta. inhibitors
EA202191152A1 (ru) 2018-10-29 2022-01-19 Миокардиа, Инк. Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
MX2023002024A (es) 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
CN114149423B (zh) * 2020-09-08 2023-12-12 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114456163B (zh) * 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CN119053591A (zh) 2022-05-20 2024-11-29 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的晶型及制备方法
IL318417A (en) 2022-07-29 2025-03-01 Myokardia Inc Crystalline forms of (6s,7s)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2h-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2 ,3-d]pyrimidine-2,4(lh,3h)-dione

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205223A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Pyrimidinedione compounds against cardiac conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725689B2 (en) 1995-06-07 2000-10-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
EA202191152A1 (ru) 2018-10-29 2022-01-19 Миокардиа, Инк. Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205223A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Pyrimidinedione compounds against cardiac conditions

Also Published As

Publication number Publication date
FI4464321T3 (fi) 2026-03-11
TWI876902B (zh) 2025-03-11
IL282740A (en) 2021-06-30
JP2025138748A (ja) 2025-09-25
JP2024063091A (ja) 2024-05-10
EP4736855A2 (en) 2026-05-06
US11034693B2 (en) 2021-06-15
AU2019373206B2 (en) 2024-11-14
PT3873904T (pt) 2024-10-08
PL3873904T3 (pl) 2024-12-23
ES2986923T3 (es) 2024-11-13
AR116880A1 (es) 2021-06-23
WO2020092208A1 (en) 2020-05-07
TWI837202B (zh) 2024-04-01
KR20210086673A (ko) 2021-07-08
JP7703716B2 (ja) 2025-07-15
SI4464321T1 (sl) 2026-03-31
CN119977963A (zh) 2025-05-13
TW202426449A (zh) 2024-07-01
US20250282779A1 (en) 2025-09-11
SMT202400358T1 (it) 2024-11-15
HUE068265T2 (hu) 2024-12-28
US20240025894A1 (en) 2024-01-25
CO2021005540A2 (es) 2021-07-30
KR102797129B1 (ko) 2025-04-18
SI3873904T1 (sl) 2024-10-30
RS65963B1 (sr) 2024-10-31
JP7447110B2 (ja) 2024-03-11
DK3873904T3 (da) 2024-08-05
HRP20260161T1 (hr) 2026-03-27
EP4464321A2 (en) 2024-11-20
MX2021004955A (es) 2021-07-21
EP3873904B1 (en) 2024-07-10
AU2019373206A1 (en) 2021-06-17
TW202521537A (zh) 2025-06-01
CN113056465A (zh) 2021-06-29
LT4464321T (lt) 2026-03-25
BR112021008077A2 (pt) 2021-08-03
CN119977962A (zh) 2025-05-13
EA202191152A1 (ru) 2022-01-19
EP3873904A1 (en) 2021-09-08
IL325304A (en) 2026-02-01
HRP20241065T1 (hr) 2024-11-08
EP4464321A3 (en) 2025-01-01
DK4464321T3 (da) 2026-02-09
LT3873904T (lt) 2024-11-11
JP2022506524A (ja) 2022-01-17
EP4464321B1 (en) 2026-01-21
MX2024004892A (es) 2024-05-07
SG11202104218SA (en) 2021-05-28
IL282740B1 (en) 2026-01-01
US20220340569A1 (en) 2022-10-27
US12344607B2 (en) 2025-07-01
CA3118293A1 (en) 2020-05-07
TW202030189A (zh) 2020-08-16
AU2025200975A1 (en) 2025-03-06
CL2021001083A1 (es) 2021-09-24
KR20250053228A (ko) 2025-04-21
US20220106314A1 (en) 2022-04-07
PE20211780A1 (es) 2021-09-08
US20200165247A1 (en) 2020-05-28
FI3873904T3 (fi) 2024-08-09

Similar Documents

Publication Publication Date Title
CN113056465B (zh) 经四氢吡喃(thp)取代的双环嘧啶二酮化合物
US20230158027A1 (en) Methods of treatment with myosin modulator
TWI504599B (zh) 倍米羅樂（ｐｅｍｉｒｏｌａｓｔ）的新結晶形式
HK40119292A (en) Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds
HK40061965A (en) Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds
HK40061965B (en) Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds
EA046692B1 (ru) Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
EA053114B1 (ru) Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
EA050645B1 (ru) Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
WO2009153261A1 (en) HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant